Research Article

Role of Uric Acid Levels as a Prognostic Indicator in Allogeneic Hematopoietic Stem Cell Transplantation: Insights from a Single-Center Study

Volume: 46 Number: 2 June 29, 2024
TR EN

Role of Uric Acid Levels as a Prognostic Indicator in Allogeneic Hematopoietic Stem Cell Transplantation: Insights from a Single-Center Study

Abstract

Uric acid (UA) acts as a richly available water-soluble antioxidant, contributing to approximately two-thirds of the overall free-radical-scavenging activity in human serum. It is discharged from damaged cells during the preparation for allogeneic hematopoietic stem cell transplantation (allo-HSCT). This study assessed how pretransplantation uric acid levels influence survival and mortality in allo-HSCT patients. In a retrospective analysis of 267 patients with hematologic diseases who underwent allo-HSCT, uric acid levels were documented on the day of allo-HSCT (day 0). Patients were divided into two cohorts based on their pretransplant uric acid levels: those at or below 4.4 mg/dL and those above 4.4 mg/dL. Among them, 153 (57.3%) were male, and 114 (42.7%) were female, with a median age of 31 years (ranging from 13 to 66). Those with serum uric acid levels of 4.4 mg/dL or lower exhibited notably poorer overall survival (OS) and disease-free survival (DFS) compared to those surpassing 4.4 mg/dL (p=0.032 and p=0.045, respectively). Our findings indicate an interrelation between low pretransplant serum uric acid levels and reduced survival rates in allo-HSCT patients. Further exploration into potential mechanisms, such as compromised antioxidative capacity in hypouricemia, may establish uric acid as a promising prognostic marker in allo-HSCT.

Keywords

References

  1. Arcangelo L, Margherita N, Francesca M, Raffaele LR, Emanuela T. Hematopoietic Stem Cell Transplantation: A Bioethical Lens. Stem Cells International 2017;2017: 1286246.
  2. Lu Z, Shanquan C, Panxin Y, Hongcui C, Lanjuan L. The role of mesenchymal stem cells in hematopoietic stem cell transplantation: prevention and treatment of graf-versus host disease. Stem Cell Research & Therapy. 2019;21;10(1):182.
  3. Yao-Chung L, Sheng-Hsuan C, Nai-Wen F, et al. Prognostic Factors on the Graft- versus-Host Disease-Free and Relapse-Free Survival after Adult Allogeneic Hematopoietic Stem Cell Transplantation. Stem Cells International 2016. 5143071.
  4. John R W, Jack H, John W H. Wingard JR, Hsu JH, Heimenz JW. Hematopoietic stem cell transplantation: an overview of infection risks and epidemiology. Infect. Dis. Clin. North. Am. 2010;24(2):257-72. https://doi:10.1016/j.idc.2010.01.010
  5. Ugur S, Selami KT, Pinar AA, Atilla E, Taner D. An overview of infectious complications after allogeneic hematopoietic stem cell transplantation. Journal of Infection and Chemotherapy 2016;22(8):505-14. https://doi: 10.1016/j.jiac.2016.05.006.
  6. Navneet SM. Long Term Complications After Hematopoietic Cell Transplantation. Hematol Oncol Stem Cell Ther 2017;10(4):220-27. https://doi:10.1016/j.hemonc.2017.05.009
  7. Akifumi K, Yusuke N, Yasuka M. et al. Role of Uric Acid Metabolism-Related Inflammation in the Pathogenesis of Metabolic Syndrome Components Such as Atherosclerosis and Nonalcoholic Steatohepatitis. Mediators of Inflammation 2016;2016:8603134. https://doi: 10.1155/ 2016/8603164
  8. Cristine E B, Joshua M H. Xanthine oxidoreductase and cardiovascular disease: molecular mechanisms and pathophysiological implications. Journal of Physiology 2004;16;555:589-606. https://doi:10.1113/jphysiol.2003. 055913

Details

Primary Language

English

Subjects

Medical Education

Journal Section

Research Article

Publication Date

June 29, 2024

Submission Date

January 30, 2024

Acceptance Date

June 9, 2024

Published in Issue

Year 2024 Volume: 46 Number: 2

AMA
1.Mandacı Şanlı N, Keklik M, Ünal A. Role of Uric Acid Levels as a Prognostic Indicator in Allogeneic Hematopoietic Stem Cell Transplantation: Insights from a Single-Center Study. CMJ. 2024;46(2):121-128. doi:10.7197/cmj.1428410

Cited By